These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 35394087)

  • 1. Two-week prospective observational study of 5% sofpironium bromide gel in Japanese patients with primary axillary hyperhidrosis.
    Fujimoto T; Okatsu H; Miyama H
    J Dermatol; 2022 Jun; 49(6):594-599. PubMed ID: 35394087
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase 3, multicenter, randomized, double-blind, vehicle-controlled, parallel-group study of 5% sofpironium bromide (BBI-4000) gel in Japanese patients with primary axillary hyperhidrosis.
    Yokozeki H; Fujimoto T; Abe Y; Igarashi M; Ishikoh A; Omi T; Kanda H; Kitahara H; Kinoshita M; Nakasu I; Hattori N; Horiuchi Y; Maruyama R; Mizutani H; Murakami Y; Watanabe C; Kume A; Hanafusa T; Hamaguchi M; Yoshioka A; Egami Y; Matsuo K; Matsuda T; Akamatsu M; Yorozuya T; Takayama S
    J Dermatol; 2021 Mar; 48(3):279-288. PubMed ID: 33410265
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase III, 52-week, open-label study to evaluate the safety and efficacy of 5% sofpironium bromide (BBI-4000) gel in Japanese patients with primary axillary hyperhidrosis.
    Fujimoto T; Abe Y; Igarashi M; Ishikoh A; Omi T; Kanda H; Kitahara H; Kinoshita M; Nakasu I; Hattori N; Horiuchi Y; Maruyama R; Mizutani H; Murakami Y; Watanabe C; Kume A; Hanafusa T; Hamaguchi M; Yoshioka A; Egami Y; Matsuo K; Matsuda T; Akamatsu M; Yorozuya T; Takayama S; Yokozeki H
    J Dermatol; 2021 Aug; 48(8):1149-1161. PubMed ID: 34041788
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sofpironium Bromide: First Approval.
    Paik J
    Drugs; 2020 Dec; 80(18):1981-1986. PubMed ID: 33236266
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of topical sofpironium bromide gel for the treatment of axillary hyperhidrosis: A phase II, randomized, controlled, double-blinded trial.
    Kirsch B; Smith S; Cohen J; DuBois J; Green L; Baumann L; Bhatia N; Pariser D; Liu PY; Chadha D; Walker P
    J Am Acad Dermatol; 2020 Jun; 82(6):1321-1327. PubMed ID: 32068049
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of 5% sofpironium bromide gel in Duchenne muscular dystrophy with palmoplantar hyperhidrosis: A retrospective case study.
    Funato M; Iwata R; Iimoto M
    J Dermatol; 2024 Jan; 51(1):135-139. PubMed ID: 37795807
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sofpironium bromide: an investigational agent for the treatment of axillary hyperhidrosis.
    Gregoriou S; Tsiogka A; Kontochristopoulos G; Offidani A; Campanati A
    Expert Opin Investig Drugs; 2022 Jan; 31(1):15-21. PubMed ID: 34890517
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Topical Glycopyrronium Tosylate for the Treatment of Primary Axillary Hyperhidrosis: Patient-Reported Outcomes from the ATMOS-1 and ATMOS-2 Phase III Randomized Controlled Trials.
    Pariser DM; Hebert AA; Drew J; Quiring J; Gopalan R; Glaser DA
    Am J Clin Dermatol; 2019 Feb; 20(1):135-145. PubMed ID: 30378087
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hyperhidrosis Disease Severity Measure-Axillary (HDSM-Ax): Evaluation of Measurement Performance.
    Hobart J; Burke L; Kirsch B; Chadha D
    J Drugs Dermatol; 2021 Apr; 20(4):410-418. PubMed ID: 33852243
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glycopyrronium tosylate in pediatric primary axillary hyperhidrosis: Post hoc analysis of efficacy and safety findings by age from two phase three randomized controlled trials.
    Hebert AA; Glaser DA; Green L; Werschler WP; Forsha DW; Drew J; Gopalan R; Pariser DM
    Pediatr Dermatol; 2019 Jan; 36(1):89-99. PubMed ID: 30451318
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Topical glycopyrronium tosylate in Japanese patients with primary axillary hyperhidrosis: A randomized, double-blind, vehicle-controlled study.
    Yokozeki H; Fujimoto T; Wanatabe S; Ogawa S; Fujii C
    J Dermatol; 2022 Jan; 49(1):86-94. PubMed ID: 34636057
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of methantheline bromide (Vagantin(®) ) in axillary and palmar hyperhidrosis: results from a multicenter, randomized, placebo-controlled trial.
    Müller C; Berensmeier A; Hamm H; Dirschka T; Reich K; Fischer T; Rzany B
    J Eur Acad Dermatol Venereol; 2013 Oct; 27(10):1278-84. PubMed ID: 23004926
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The efficacy and safety of a fractional microneedle radiofrequency device for the treatment of axillary hyperhidrosis: clinical prospective pilot study.
    Jung JM; Na HM; Kim JH; Yoon J; Yang HJ; Lee WJ; Chang SE; Lee MW; Won CH
    Lasers Med Sci; 2022 Apr; 37(3):1559-1566. PubMed ID: 34453655
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Prospective, Nonrandomized, Open-Label Study of the Efficacy and Safety of OnabotulinumtoxinA in Adolescents with Primary Axillary Hyperhidrosis.
    Glaser DA; Pariser DM; Hebert AA; Landells I; Somogyi C; Weng E; Brin MF; Beddingfield F
    Pediatr Dermatol; 2015; 32(5):609-17. PubMed ID: 26059781
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The application of microwaves in axillary hyperhidrosis: Curative effect observation of a pathological examination over 1 year.
    Tan Y; Huang W; Liu J; Duan Z; He X; Li Q; Yang Z
    J Cosmet Dermatol; 2024 Jan; 23(1):134-140. PubMed ID: 37547985
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A 44-Week Open-Label Study Evaluating Safety and Efficacy of Topical Glycopyrronium Tosylate in Patients with Primary Axillary Hyperhidrosis.
    Glaser DA; Hebert AA; Nast A; Werschler WP; Green L; Mamelok RD; Quiring J; Drew J; Pariser DM
    Am J Clin Dermatol; 2019 Aug; 20(4):593-604. PubMed ID: 31111409
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A glycopyrronium bromide 1% cream for topical treatment of primary axillary hyperhidrosis: efficacy and safety results from a phase IIIa randomized controlled trial.
    Abels C; Soeberdt M; Kilic A; Reich H; Knie U; Jourdan C; Schramm K; Heimstaedt-Muskett S; Masur C; Szeimies RM
    Br J Dermatol; 2021 Aug; 185(2):315-322. PubMed ID: 33445205
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comparative study between intradermal botulinum toxin A and fractional microneedle radiofrequency (FMR) for the treatment of primary axillary hyperhidrosis.
    Rummaneethorn P; Chalermchai T
    Lasers Med Sci; 2020 Jul; 35(5):1179-1184. PubMed ID: 31939036
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical evaluation and quantitative analysis of axillary hyperhidrosis treated with a unique targeted laser energy delivery method with 1-year follow up.
    Caplin D; Austin J
    J Drugs Dermatol; 2014 Apr; 13(4):449-56. PubMed ID: 24719065
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fractionated microneedle radiofrequency for treatment of primary axillary hyperhidrosis: A sham control study.
    Fatemi Naeini F; Abtahi-Naeini B; Pourazizi M; Nilforoushzadeh MA; Mirmohammadkhani M
    Australas J Dermatol; 2015 Nov; 56(4):279-84. PubMed ID: 25496000
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.